ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, today announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI ...

Core Insights - CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders [1][2] - SRSD107 has shown promising results in Phase 1 clinical trials, achieving over 93% reduction in FXI activity and more than twofold increase in activated partial thromboplastin time (aPTT), with effects lasting up to 6 months post-dosing [1][3] - The collaboration includes an upfront payment of $25 million in cash and $70 million in equity from CRISPR to Sirius, with a 50-50 cost and profit-sharing structure for SRSD107 [1][8] Company Overview - CRISPR Therapeutics is focused on creating transformative gene-based medicines and has a diverse portfolio across various disease areas, including cardiovascular diseases [10] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with SRSD107 being its most advanced product targeting thromboembolic disorders [17][18] Clinical Development - The clinical program for SRSD107 includes two Phase 1 trials demonstrating safety and robust pharmacodynamic effects, with a Phase 2 trial planned to evaluate its efficacy in preventing venous thromboembolism (VTE) in total knee arthroplasty patients [3][7] - SRSD107 is designed to selectively inhibit FXI, aiming to reduce thrombotic events while minimizing bleeding risks, offering a differentiated approach compared to existing therapies [2][16] Market Potential - Thromboembolic disorders are a significant global health issue, affecting millions and representing a substantial unmet medical need [2][15] - The addressable patient population for SRSD107 includes those with atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and other conditions where existing therapies pose bleeding risks [2][3]